Merck Picks Up Hanmi’s Dual Agonist Efinopegdutide, But For NASH

Repurposed Promise In Competitive Indication

 
• By Jung Won Shin
  
liver
Hanmi’s First Major Licensing Out Deal For Years • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from South Korea

More from Focus On Asia